Acrylic acid (CH_2=CH-COOH) B 1

Information and recommendations for paramedics and doctors at the site

- **Patients whose clothing or skin is contaminated with liquid acrylic acid can cause secondary contamination of rescue and medical personnel by direct contact or through evaporation of acrylic acid. Patients exposed only to acrylic acid vapor do not pose a significant risk of secondary contamination.**
- **Acrylic acid is rapidly corrosive to all tissues. Eye contact may cause severe burns and loss of vision. Contact with the skin may cause severe burns which may be delayed in onset. Acrylic acid vapor is irritating to the skin, eyes, nose, throat and respiratory tract, causing irritation, coughing, chest pain and dyspnea. Laryngospasm and pulmonary edema (shortness of breath, cyanosis, expectoration, cough) may occur.**
- **There is no antidote to be administered to counteract the effects of acrylic acid. Treatment consists of supportive measures.**

1. Substance information

Acrylic acid ($C_3H_4O_2$), CAS 79-10-7
Synonyms: propene acid
At room temperature acrylic acid is a colorless liquid with a distinct acrid odor. Acrylic acid is used as the monomer in the manufacture of acrylic resins, especially acrylates. It is also used in the polymeric emulsions as coatings for leather; in paints, polishes, and adhesives; and in general finishes and binders.

2. Routes of exposure

Inhalation

Exposures may occur by inhalation. Acrylic acid's odor and upper respiratory tract irritant properties generally provide adequate warning of hazardous concentrations.

Skin/eye contact

Most exposures occur by direct contact of the skin and the eyes with liquid acrylic acid. Contact with the skin and the eyes causes severe burns which may be delayed in onset.

Ingestion

Ingestion causes severe corrosive injury of the mucous membranes of the throat and esophagus.

3. Acute health effects

Respiratory

Acrylic acid exposure usually causes mucous membrane irritation, sore throat, and coughing. Rapid development of respiratory distress with chest pain, dyspnea, laryngospasm and pulmonary edema (shortness of breath, cyanosis, expectoration, cough) may occur. Lung injury may progress over several hours. Acrylic acid poisoning may cause respiratory failure. Systemic absorption in humans is rare since both the liquid and vapor are irritating or corrosive.

Dermal

Deep burns of the skin and mucous membranes may be caused by contact with liquid acrylic acid; disfiguring scars may result. Contact with less concentrated acrylic acid vapor or mist can cause burning pain, redness, inflammation, and blisters.

Ocular

Eye contact causes severe burns and loss of vision. Contact with less concentrated acrylic acid vapor or mist cause burning discomfort, spasmodic blinking or involuntary closing of the eyelids, redness, and tearing.

Dose-effect relationships Dose-effect relationships are as follows:

Acrylic acid concentration		Effect
1 ppm	-	odor threshold
1,5 ppm for 10 min	-	AEGL I (acute exposure guidance level, EPA)
68 ppm for 10 min	-	AEGL II (acute exposure guidance level, EPA)
480 ppm for 10 min	-	AEGL III (acute exposure guidance level, EPA)

AEGL I (acute exposure guidelines levels): airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.
AEGL II: airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious long-lasting adverse health effects, or an impaired ability to escape
AEGL III: airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death

4. Actions

Rescuer self-protection

In response situations that involve exposure to potentially unsafe levels of acrylic acid (see below), pressure-demand, self-contained breathing apparatus and chemical-protective clothing is recommended.
Patients exposed only to acrylic acid vapor do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid acrylic acid or acrylic acid mist can secondarily contaminate other people by direct contact or through evaporation of acrylic acid.

Patient recovery

Patients should be removed from the contaminated zone immediately. Patients who are unable to walk may be removed on backboards or stretchers; if these are not available, carefully remove/transport patients with appropriate action to a safe zone, taking into account your self-protection.
Immediate priorities must follow the "**A, B, C's**" (Airway, Breathing, Circulation) of resuscitation.

Decontamination

Patients exposed only to acrylic acid vapor or mist who have no evidence of skin or eye irritation do not need decontamination. All others require decontamination.
Patients who are able and cooperative may assist with their own decontamination. If the exposure involved liquid acrylic acid and if clothing is contaminated, **remove immediately** and double-bag the clothing.
Assure that exposed or irritated eyes have been irrigated with plain water or saline for at least 20 minutes, and that the pH of the conjunctival fluid has returned to normal (7.0). If not, continue eye irrigation during other basic care and transport. If eye irrigation is impaired by blepharospasm, one to two drops of oxybuprocaine 0.4% may be instilled into affected eyes to allow adequate irrigation.
Remove contact lenses if present and easily removable without additional trauma to the eye.
Assure that exposed skin and hair have been flushed with plain water for at least 15 minutes. If not, continue flushing during other basic care and transport. Protect eyes during flushing of skin and hair.

Initial treatment

Therapy will be empiric; there is no antidote to be administered to counteract the effects of acrylic acid.
The following measures are recommended if the airborne exposure concentration is 50 ppm or greater (depending on time exposed), if symptoms, e. g. eye irritation or pulmonary symptoms have developed, or if no exposure concentration can be estimated but exposure has possibly occurred:

- **Administration of oxygen**

- **Administration of 8 puffs of beclomethasone (800 µg beclomethasone dipropionate) from a metered dose inhaler.**

Patients with severe clinical respiratory symptoms (e.g. bronchospasms, stridor) should be treated as follows:
a) Nebulization of adrenaline (epinephrine): 2 mg adrenaline (2 ml) with 3 ml NaCl 0.9% and inhale through a nebulizer mask.

b) Administration of a ß2-selective adrenoceptor agonist, e.g., four strokes of terbutaline or salbutamol or fenoterol (one stroke usually contains 0.25 mg of terbutaline sulfate; or 0.1 mg of salbutamol; or 0.2 mg of fenoterol); this may be repeated once after 10 minutes. Alternatively, 2.5 mg salbutamol and 0.5 mg atrovent may be administered by nebulizer mask.
If inhalation is not possible, administration of terbutaline sulfate (0.25 mg to 0.5 mg) subcutaneously or salbutamol (0.2 mg to 0.4 mg over 15 minutes) intravenously.

c) Intravenous administration of 250 mg methylprednisolone (or equivalent steroid dose).

Patients with clinical signs of a toxic lung edema (e.g. foamy sputum, wet crackles) should be treated as follows:
a) Start CPAP-therapy (Continuous Positive Airway Pressure Ventilation).
b) Intravenous administration of 1000 mg methylprednisolone (or an equivalent steroid dose) is recommended.

Intubation of the trachea or an alternative airway management should be considered in cases of respiratory compromise. When the patient's condition precludes this, consider cricothyrotomy if equipped and trained to do so.

Note: Efficacy of corticosteroid administration has not yet been proven in controlled clinical studies.
.
Patients exposed to an airborne concentration of 50 ppm or greater (depending on time exposed) and patients without available exposure measurements but suspected of being exposed to concentrations of 50 ppm or greater (depending on time exposed) should be transferred to a hospital/emergency department.
If acrylic acid was in contact with the skin, chemical burns may result; treat as thermal burns: adequate fluid resuscitation and administration of analgesics, maintenance of the body temperature, covering of the burn with a sterile pad or clean sheet.
After eye exposure chemical burns may result; treat as thermal burns. Immediately consult an ophthalmologist.
Note: Any facial exposure to liquid acrylic acid should be considered as a serious exposure.

Patient release/ follow-up instructions

Asymptomatic patients exposed to an airborne concentration of **less than 50 ppm** (depending on the period of time exposed) **as well as patients who have a normal clinical examination and no signs or symptoms of toxicity may be discharged after an appropriate observation period in the following circumstances:**

a) The evaluating physician is experienced in the evaluation of

individuals with acrylic acid or irritant gas exposure.

b) Information and recommendations for patients with follow-up instructions are provided verbally and in writing. Patients are advised to seek medical care promptly if symptoms develop or recur.
c) The physician is comfortable that the patient understands the health effects of acrylic acid and the provided follow-up instructions.
d) Site medical is notified, so that the patient may be contacted at regular intervals in the 24-hour period following release.
e) Heavy physical work should be precluded for up to 24 hours. Patients who have serious skin or eye injuries should be reexamined in 24 hours.
f) Exposure to cigarette smoke should be avoided for 72 hours; the smoke may worsen the condition of the lungs. Patients who have serious skin or eye injuries should be reexamined in 24 hours.

Post discharge spirometry should be repeated until values return to the patient's baseline values.

BASF SE
Corporate Health Management
Carl-Bosch-Straße 38
67056 Ludwigshafen
Germany

BASF Corporation
Medical Department
100 Campus Drive, M/S F 221
Florham Park, NJ 07932
USA